Greenwich Lifesciences, INC Form 4 insider transactions

Jaye Thompson, VP of Clinical and Regulatory Affairs at Greenwich LifeSciences, purchased 800 shares of GLSI at $13.85 per share on August 12, 2024.

Snehal Patel, CEO and CFO of Greenwich LifeSciences, recently purchased 2,000 shares of the company's common stock at a price of $13.81 per share.

Greenwich LifeSciences CEO Snehal Patel reports purchasing 5,500 shares of GLSI common stock at $13.18 per share on August 5, 2024.

Jaye Thompson, VP of Clinical and Regulatory Affairs at Greenwich LifeSciences, purchased 1,000 shares of common stock at $15.15 per share on August 2, 2024.

Snehal Patel, CEO and CFO of Greenwich LifeSciences, recently purchased 1,500 shares of common stock at $15.89 per share.

Jaye Thompson, VP of Clinical and Regulatory Affairs at Greenwich LifeSciences, purchased 1,000 shares of GLSI at $16 per share on July 18, 2024.

Snehal Patel, CEO and CFO of Greenwich LifeSciences, disposed of 174,825 shares of common stock at a price of $14.3 per share on June 13, 2024.

Greenwich LifeSciences CEO Snehal Patel reports the acquisition of 3,000 shares of common stock at a price of $19.08 per share on April 1, 2024.

Snehal Patel, CEO and CFO of Greenwich LifeSciences, reports purchasing 2,500 shares of common stock at $19.98 per share on March 22, 2024, increasing their total holdings.

Snehal Patel, CEO and CFO of Greenwich LifeSciences, recently purchased 1,500 shares of common stock at $17.68 per share, increasing their total holdings.

Greenwich LifeSciences CEO Snehal Patel purchased 3,500 shares of common stock at $12.49 per share on March 5, 2024, according to a Form 4/A filing.

Snehal Patel, CEO and CFO of Greenwich LifeSciences, purchased 30,500 shares of the company's common stock at a price of $12.49 per share on March 5, 2024.

Snehal Patel, CEO and CFO of Greenwich LifeSciences, purchased 4,100 shares of common stock at $13.03 per share on March 4, 2024.